Sartorius reported a strong set of Q1 22 numbers as sales rose 25.4%, driven by broad-based growth. The EBITDA margin rose to 34.1% (+80bps), as operational leverage more than offset the currency headwinds.
Order intake was down 5.8%, largely attributable to the expected decline in bioprocessing. Encouragingly, the order intake figures were up sequentially.
FY 22 guidance – 15-19% top-line growth and a 34% EBITDA margin – was surprisingly unchanged.
We will upgrade our forecasts to reflect th ....
22 Apr 2022
Strong Q1 leaves room for FY 22 guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q1 leaves room for FY 22 guidance upgrade
Sartorius reported a strong set of Q1 22 numbers as sales rose 25.4%, driven by broad-based growth. The EBITDA margin rose to 34.1% (+80bps), as operational leverage more than offset the currency headwinds.
Order intake was down 5.8%, largely attributable to the expected decline in bioprocessing. Encouragingly, the order intake figures were up sequentially.
FY 22 guidance – 15-19% top-line growth and a 34% EBITDA margin – was surprisingly unchanged.
We will upgrade our forecasts to reflect th ....